Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Announces Quarterly Earnings Results

by · The Cerbat Gem

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($3.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($2.78), FiscalAI reports. The firm had revenue of $0.79 million during the quarter, compared to analyst estimates of $0.74 million.

Armata Pharmaceuticals Price Performance

Shares of ARMP stock traded down $0.18 during trading hours on Wednesday, reaching $8.82. The company had a trading volume of 27,167 shares, compared to its average volume of 78,655. The stock has a fifty day moving average of $10.50 and a 200-day moving average of $8.12. Armata Pharmaceuticals has a 12-month low of $1.17 and a 12-month high of $16.34.

Analyst Ratings Changes

Separately, HC Wainwright lifted their price target on Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $15.00.

View Our Latest Analysis on ARMP

Institutional Investors Weigh In On Armata Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its holdings in Armata Pharmaceuticals by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock valued at $690,000 after acquiring an additional 5,342 shares during the last quarter. State Street Corp lifted its holdings in Armata Pharmaceuticals by 26.1% in the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after acquiring an additional 10,500 shares during the last quarter. Jane Street Group LLC acquired a new position in Armata Pharmaceuticals in the fourth quarter valued at approximately $108,000. Millennium Management LLC acquired a new position in Armata Pharmaceuticals in the fourth quarter valued at approximately $164,000. Finally, Renaissance Technologies LLC lifted its holdings in Armata Pharmaceuticals by 65.9% in the fourth quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock valued at $430,000 after acquiring an additional 27,200 shares during the last quarter. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

(Get Free Report)

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.

Featured Stories